Albuterol HFA 90 mcg inhaler — Membership Pricing

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for COPD

• Ipratropium
• Tiotropium
• Ipratropium 17 mcg inhaler
• Tiotropium 18 mcg caps for inhalation

About Albuterol HFA 90 mcg inhaler

Albuterol HFA 90 mcg is a vital rescue inhaler for millions managing asthma and COPD. When every breath counts, affordable access to your medication is crucial. TheDrugClub understands this, offering significant savings on essential prescriptions like albuterol, ensuring you get the relief you need without the financial burden.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Albuterol HFA 90 mcg inhaler is approved for (FDA label)

Albuterol Sulfate Inhalation Aerosol is a beta 2 -adrenergic agonist indicated for: Treatment or prevention of bronchospasm in patients 4 years of age and older with reversible obstructive airway disease. ( 1.1 ) Prevention of exercise-induced bronchospasm in patients 4 years of age and older. ( 1.2 ) 1.1 Bronchospasm Albuterol Sulfate Inhalation Aerosol is indicated for the treatment or prevention of bronchospasm in patients 4 years of age and older with reversible obstructive airway disease. 1.2 Exercise-Induced Bronchospasm Albuterol Sulfate Inhalation Aerosol is indicated for the prevention of exercise-induced bronchospasm in patients 4 years of age and older.

Source: Read the full FDA label on DailyMed. Label effective date: August 6, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Albuterol HFA 90 mcg inhaler (FDA label)

Albuterol Sulfate is an inhalation aerosol. Albuterol Sulfate Inhalation Aerosol is supplied as an 8.5 g/200 actuations pressurized aluminum canister with a green plastic actuator with a dose counter and yellow dust cap each in boxes of one. Each actuation delivers 120 mcg of albuterol sulfate from the canister valve and 108 mcg of albuterol sulfate from the actuator mouthpiece (equivalent to 90 mcg of albuterol base). Inhalation Aerosol: Each actuation delivers 108 mcg of albuterol sulfate from the actuator mouthpiece (equivalent to 90 mcg of albuterol base). Supplied in 8.5-g canister containing 200 actuations.

Source: FDA prescribing information (DailyMed). Set ID: 17858afa-dcdf-4612-b475-3b6baadfb639. SPL document ID: aabe1b11-7f84-4db3-9d05-0c79a4a88ba2. Label effective date: August 6, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Albuterol HFA 90 mcg inhaler (FDA label)

Use of Albuterol Sulfate may be associated with the following: Paradoxical bronchospasm [see Warnings and Precautions ( 5.1 ) ] Cardiovascular Effects [see Warnings and Precautions ( 5.4 ) ] Immediate hypersensitivity reactions [see Warnings and Precautions ( 5.6 ) ] Hypokalemia [see Warnings and Precautions ( 5.8 ) ] Most common adverse reactions (≥3.0% and >placebo) are headache, tachycardia, pain, dizziness, pharyngitis, and rhinitis. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Armstrong Pharmaceuticals, Inc. at 1-800-423-4136 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience A total of 1090 subjects were treated with Albuterol Sulfate Inhalation Aerosol, or with the same formulation of albuterol as in Albuterol Sulfate Inhalation Aerosol, during the worldwide clinical development program.

Source: FDA prescribing information (DailyMed). Set ID: 17858afa-dcdf-4612-b475-3b6baadfb639. SPL document ID: aabe1b11-7f84-4db3-9d05-0c79a4a88ba2. Label effective date: August 6, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Albuterol HFA 90 mcg inhaler (FDA label)

Albuterol Sulfate Inhalation Aerosol is contraindicated in patients with a history of hypersensitivity to albuterol and any other Albuterol Sulfate Inhalation Aerosol components. Rare cases of hypersensitivity reactions, including urticaria, angioedema, and rash have been reported after the use of albuterol sulfate [see Warnings and Precautions ( 5.6 ) ] . Hypersensitivity to albuterol and any other Albuterol Sulfate Inhalation Aerosol Components.

Source: FDA prescribing information (DailyMed). Set ID: 17858afa-dcdf-4612-b475-3b6baadfb639. SPL document ID: aabe1b11-7f84-4db3-9d05-0c79a4a88ba2. Label effective date: August 6, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Albuterol HFA 90 mcg inhaler (FDA label)

Life-threatening paradoxical bronchospasm may occur. Discontinue Albuterol Sulfate Inhalation Aerosol immediately and treat with alternative therapy. ( 5.1 ) Need for more doses of Albuterol Sulfate Inhalation Aerosol than usual may be a sign of deterioration of asthma and requires reevaluation of treatment. ( 5.2 ) Albuterol Sulfate Inhalation Aerosol is not a substitute for corticosteroids. ( 5.3 ) Cardiovascular effects may occur. Use with caution in patients sensitive to sympathomimetic drugs and patients with cardiovascular or convulsive disorders. ( 5.4 , 5.7 ) Excessive use may be fatal. Do not exceed recommended dose. ( 5.5 ) Immediate hypersensitivity reactions may occur. Discontinue Albuterol Sulfate Inhalation Aerosol immediately. ( 5.6 ) Hypokalemia and changes in blood glucose may occur. ( 5.7 , 5.8 ) 5.1 Paradoxical Bronchospasm Albuterol Sulfate Inhalation Aerosol can produce paradoxical bronchospasm that may be life threatening.

Source: FDA prescribing information (DailyMed). Set ID: 17858afa-dcdf-4612-b475-3b6baadfb639. SPL document ID: aabe1b11-7f84-4db3-9d05-0c79a4a88ba2. Label effective date: August 6, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Albuterol HFA 90 mcg inhaler (FDA label)

Other short-acting sympathomimetic aerosol bronchodilators should not be used concomitantly with Albuterol Sulfate Inhalation Aerosol. If additional adrenergic drugs are to be administered by any route, they should be used with caution to avoid deleterious cardiovascular effects. Other short-acting sympathomimetic aerosol bronchodilators and adrenergic drugs: May potentiate effect. ( 7 ) Beta-blockers: May decrease effectiveness of Albuterol Sulfate and produce severe bronchospasm. Patients with asthma should not normally be treated with beta-blockers. ( 7.1 ) Diuretics, or non-potassium sparing diuretics: May potentiate hypokalemia or ECG changes. Consider monitoring potassium levels. ( 7.2 ) Digoxin: May decrease serum digoxin levels. Consider monitoring digoxin levels. ( 7.3 ) Monoamine oxidase (MAO) inhibitors and tricyclic antidepressants: May potentiate effect of albuterol on the cardiovascular system.

Source: FDA prescribing information (DailyMed). Set ID: 17858afa-dcdf-4612-b475-3b6baadfb639. SPL document ID: aabe1b11-7f84-4db3-9d05-0c79a4a88ba2. Label effective date: August 6, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.